Treatment of severe life threatening hypocalcemia with recombinant human teriparatide in patients with postoperative hypoparathyroidism - a case series.
- Elżbieta Andrysiak-Mamos,
- Ewa Żochowska,
- Agnieszka Kaźmierczyk-Puchalska,
- Michał Popow,
- Dorota Kaczmarska-Turek,
- Janusz Pachucki,
- Tomasz Bednarczuk,
- Anhelli Syrenicz
Endokrynol Pol 2016 8;67(4):403-12. Epub 2016 Jul 8.
Department of Endocrinology, Metabolic Diseases, and Internal Diseases, Pomeranian Medical University, Szczecin, Poland.
Introduction: Hypocalcaemia is a common postoperative complication, both after the resection of parathyroid adenoma associated with primary hyperparathyroidism and after total thyroidectomy due to thyroid cancer or nodular goitre. For a few years, in patients with postoperative hypoparathyroidism and severe hypocalcaemia, who cannot discontinue intravenous calcium preparations even with the use of high vitamin D doses, attempts have been made to add recombinant human parathormone (rhPTH) to the treatment schedule. In this work, for the first time in Poland, we demonstrate the potential use of teriparatide for the treatment of severe hypocalcaemia based on three different cases of postoperative hypoparathyroidism. Read More